Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas.
Fifteen patients with advanced adenocarcinoma of the pancreas were treated with menogarol 150-225 mg/m2 i.v. every 3 weeks. All patients had bidimensionally measurable disease. This regimen and dosage schedule are well tolerated, with minimal toxicity that included myelosupression; median white blood cell (WBC) count nadir of 2,700 cells/mm3 (range 1,400-7,100 cells/mm3) and median platelet nadir of 162,000 cells/mm3 (range 53,000-390,000 cells/mm3). Anorexia occurred in one patient, nausea or vomiting in six, phlebitis in one, and alopecia in six patients. No patients responded. At this dosage and schedule, there is no role for menogarol in the treatment of advanced pancreatic adenocarcinoma.
Sternberg
C N
CN
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Magill
G B
GB
Cheng
E W
EW
Hollander
P
P
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003630:Daunorubicin / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D017290:Menogaril; D008875:Middle Aged; D009621:Nogalamycin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
D017290:Menogaril; D009621:Nogalamycin; D003630:Daunorubicin